title: Single high-dose intravenous immunoglobulin therapy for kawasaki disease increases plasma viscosity.
abstract: BACKGROUND
  Intravenous immunoglobulin therapy, widely used for various autoimmune and systemic inflammatory diseases including Kawasaki disease (KD), is occasionally associated with thromboembolic adverse effects caused by an abrupt increase in blood viscosity. Scarce information is available, however, regarding the effect of single high-dose immunoglobulin therapy for KD on blood viscosity.
  
  
  RESULTS
  Eleven boys and 5 girls (mean age: 2.1 years) with acute-phase KD underwent single high-dose immunoglobulin therapy. Plasma viscosity before the treatment was 1.18 centipoises (SD = 0.06), but it significantly rose to 1.34 centipoises (SD = 0.06) (p < 0.001). Multiple regression analysis revealed that, among various factors including hematocrit, plasma concentrations of total protein, immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM), only plasma IgG concentration was included in the model to explain plasma viscosity (R2 = 0.59, p < 0.001).
  
  
  CONCLUSIONS
  Single high-dose regimen for acute-phase KD increases blood viscosity and therefore might increase the risk of thromboembolism.
authors.affiliation: Department of Paediatrics, Aichi Medical University School of Medicine, Aichi, Japan. babar@aichi-med-u.ac.jp
authors.forename: Reizo
authors.initials: R
authors.lastname: Baba
authors.forename: Atsuko
authors.initials: A
authors.lastname: Shibata
authors.forename: Masahito
authors.initials: M
authors.lastname: Tsurusawa
mesh_terms: D001809:Blood Viscosity / Q000187:drug effects; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D007070:Immunoglobulin A / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000097:blood* / Q000188:drug therapy*; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology
chemical_list: D007070:Immunoglobulin A; D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous